# US 2022/0033918 A1 · Co-binder assisted assay methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033918 A1
- Document ID: US20220033918A1
- Status: Published application
- Kind: A1
- Application number: 17/504,937
- Filed: 2021-10-19
- Published: 2022-02-03
- Earliest claimed: 2011-11-11
- Assignees: Meso Scale Technologies, LLC.
- Applicants: Meso Scale Technologies, LLC.
- Inventors: Eli N. Glezer; George Sigal
- Web page: https://patentgrep.com/patent/US20220033918A1

## CPC

- C12Q 1/70: involving virus or bacteriophage {(immunoassay for viruses G01N33/56983)}
- C12Q 1/6813: Hybridisation assays
- C12Q 1/6834: Enzymatic or biochemical coupling of nucleic acids to a solid phase
- G01N 33/542: with steric inhibition or signal modification, e.g. fluorescent quenching
- G01N 33/54333: {Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention is directed to methods for reducing cross-reactivity between species employed in multiplexed immunoassays.

## Claims

### Claim at position 1

-55. (canceled)

### Claim 56

A kit configured to conduct a binding assay comprising a solid surface comprising:
(i) a first binding reagent immobilized thereto comprising a first binding region that binds to said analyte of interest, wherein said first binding reagent is linked to a first linking agent comprising a first oligonucleotide sequence;
(ii) a second binding reagent comprising a second binding region that binds to said analyte of interest, wherein said second binding reagent is linked to a second linking agent comprising a second oligonucleotide sequence, and
(iii) a bridging oligonucleotide sequence comprising a sequence complementary to at least a portion of said first oligonucleotide sequence and said second oligonucleotide sequence.

### Claim 57

A kit configured to conduct a binding assay for a plurality of analytes comprising:
(i) a solid surface including one or more first binding reagents immobilized thereto, wherein said one or more first binding reagents each comprise a first binding region that binds to said analytes and each of said one or more first binding reagents are linked to a first linking agent comprising a first oligonucleotide sequence;
(ii) one or more second binding reagents each comprising a second binding region that binds to said analyte of interest, wherein said second binding reagent is linked to a second linking agent comprising a second oligonucleotide sequence, and
(iii) one or more bridging oligonucleotide sequences each comprising a sequence complementary to at least a portion of said first oligonucleotide sequence and said second oligonucleotide sequence.

### Claim 58 (depends on 56)

The kit of claim 56, wherein said first binding region is specific for said analyte of interest.

### Claim 59 (depends on 56)

The kit of claim 56, wherein said second binding region is specific for said analyte of interest.

### Claim 60 (depends on 56)

The kit of claim 56, wherein said first binding reagent is an antibody.

### Claim 61 (depends on 56)

The kit of claim 56, wherein said second binding reagent is an antibody.

### Claim 62 (depends on 57)

The kit of claim 57, wherein said first binding region is specific for said analyte of interest.

### Claim 63 (depends on 57)

The kit of claim 57, wherein said second binding region is specific for said analyte of interest.

### Claim 64 (depends on 57)

The kit of claim 57, wherein said one or more first binding reagents are antibodies.

### Claim 65 (depends on 57)

The kit of claim 57, wherein said one or more second binding reagents are antibodies.

### Claim 66 (depends on 56)

The kit of claim 56, wherein said second binding reagent comprises a detectable label.

### Claim 67 (depends on 57)

The kit of claim 57, wherein said one or more second binding reagents comprise a detectable label.

### Claim 68 (depends on 56)

The kit of claim 56, wherein said first oligonucleotide sequence comprises about 5-15 bases.

### Claim 69 (depends on 56)

The kit of claim 56, wherein said second oligonucleotide sequence comprises about 5-15 bases.

### Claim 70 (depends on 56)

The kit of claim 56, wherein said first oligonucleotide sequence and said second oligonucleotide sequence each comprise a complementary binding sequence of about 4-8 bases in length.

### Claim 71 (depends on 57)

The kit of claim 57, wherein said first oligonucleotide sequence comprises about 5-15 bases.

### Claim 72 (depends on 57)

The kit of claim 57, wherein said second oligonucleotide sequence comprises about 5-15 bases.

### Claim 73 (depends on 57)

The kit of claim 57, wherein said first oligonucleotide sequence and said second oligonucleotide sequence each comprise a complementary binding sequence of about 4-8 bases in length.

### Claim 74 (depends on 56)

The kit of claim 56, wherein said first linking agent and/or said second linking agent further comprises a polymer unit.

### Claim 75 (depends on 57)

The kit of claim 57, wherein said first linking agent and/or said second linking agent further comprises a polymer unit.